How India Exports Diclofenac to the World

In the United States, diclofenac is approved through Abbreviated New Drug Applications (ANDAs), allowing generic manufacturers to market the drug upon demonstrating bioequivalence to the reference listed drug. The FDA's Orange Book lists multiple approved ANDAs for diclofenac, indicating a competitive market landscape. Notably, in January 2015, the FDA issued warnings against certain dietary supplements, such as Umary and Amazy, which were found to contain undeclared diclofenac, leading to import alerts and product recalls. This underscores the FDA's stringent oversight to ensure product safety and compliance.

Given that 25.1% of India's diclofenac exports are directed to the U.S., Indian exporters must adhere to FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and accurate product labeling. The presence of 1,007 active Indian exporters highlights the importance of maintaining high regulatory standards to ensure market access and competitiveness.

In the European Union, diclofenac-containing medicines require marketing authorization from national regulatory agencies or the European Medicines Agency (EMA). The EMA has conducted several reviews concerning diclofenac's safety and efficacy. For instance, in July 2016, the EMA concluded that the benefits of diclofenac epolamine 50 mg tablets did not outweigh the risks, leading to the denial of marketing authorization in certain member states. (ema.europa.eu) Conversely, in November 2018, the EMA recommended the authorization of Diclofenac Sodium Spray Gel 4%, recognizing its benefits in treating joint pain and swelling. (ema.europa.eu)

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) reclassified oral diclofenac as a prescription-only medicine in January 2015 due to cardiovascular risk concerns. (gov.uk) This regulatory shift necessitates that exporters ensure compliance with prescription requirements and updated labeling standards.

Diclofenac is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global healthcare. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards is crucial for ensuring product quality and facilitating international trade.

In India, diclofenac is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for diclofenac exports, ensuring compliance with national regulations and monitoring of controlled substances.

The primary patents for diclofenac have expired, leading to a robust generic market with significant competition. This competitive environment has contributed to the widespread availability and affordability of diclofenac globally.

In July 2024, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for topical diclofenac formulations, emphasizing risks associated with use during pregnancy. (ema.europa.eu) This highlights the importance of ongoing safety monitoring and the need for exporters to stay informed about regulatory changes.

In January 2025, the EMA completed a periodic safety update report (PSUR) assessment for systemic diclofenac formulations, resulting in variations to marketing authorizations to enhance safety information. (ema.europa.eu) This underscores the dynamic nature of regulatory requirements and the necessity for exporters to maintain compliance with evolving standards.

These developments reflect the continuous evaluation of diclofenac's safety profile and the imperative for exporters to adapt to regulatory changes to ensure market access and patient safety.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of KSMs are imported from China, making Indian API manufacturers vulnerable to supply chain disruptions. This dependency became evident during the COVID-19 pandemic when Chinese factory shutdowns led to immediate shortages and price surges in common APIs.

In response, the Indian government launched the Production Linked Incentive (PLI) scheme in October 2024 to boost domestic production of critical APIs and KSMs. Two greenfield plants were inaugurated under this initiative to manufacture essential molecules like Penicillin G and Clavulanic Acid, aiming to reduce import dependence by half. However, challenges such as cost competition, infrastructure limitations, and environmental regulations continue to impede rapid progress toward self-reliance.

Our proprietary trade data indicates that the top five exporters of Diclofenac from India account for 42.3% of the total export value, with LINCOLN PHARMACEUTICALS LTD leading at a 15.5% share. This concentration poses a risk, as disruptions affecting these key suppliers could significantly impact global Diclofenac availability. While the PLI scheme has incentivized domestic API production, its focus has been on antibiotics and other critical drugs, with limited direct impact on Diclofenac's supply chain.

Recent geopolitical events have further strained pharmaceutical supply chains. In February 2026, Iran's partial closure of the Strait of Hormuz threatened 20% of global oil supply, leading to increased maritime insurance premiums and potential delays in shipping routes critical for raw material imports. Additionally, escalating US-China tensions have raised concerns about trade restrictions and tariffs, which could disrupt the import of essential KSMs from China. While no specific FDA or EMA shortage alerts for Diclofenac have been issued recently, the interconnected nature of global supply chains means that such geopolitical disruptions could have cascading effects on API availability.

• Diversify Sourcing: Identify and qualify alternative suppliers for KSMs and APIs beyond China to reduce dependency and enhance supply chain resilience.

• Enhance Domestic Production: Expand the PLI scheme to include APIs like Diclofenac, providing incentives for domestic manufacturing and reducing reliance on imports.

• Strengthen Supplier Relationships: Develop strategic partnerships with key suppliers to ensure priority access during supply disruptions and foster collaborative risk management.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains, enabling proactive risk mitigation strategies.

• Invest in Supply Chain Transparency: Implement advanced tracking systems to gain real-time visibility into the supply chain, allowing for swift responses to disruptions and better inventory management.

RISK_LEVEL: MEDIUM